Trademarkia Logo

Australia

AU$
GONDOLABIO
Accepted: In opposition period

Last updated on 18 Mar 2025

Owner Info

Bridgebio Pharma, Inc.

3160 Porter Dr., Suite 250

Palo Alto CA 94304, UNITED STATES OF AMERICA

Serial Number

2527948 filed on 6 Feb 2025

Correspondent

Jessica L. Rothstein Goodwin Procter LLP

620 Eighth Avenue,

New York NY 10018,

UNITED STATES OF AMERICA

GONDOLABIO

Classification Information


Class [005]
Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and d Read More

Class [042]
Pharmaceutical research and development services.

Mark Details


Serial Number

2527948

Registered On

NA

Renewal On

NA

Mark Type

WORD

Priority Claim (Convention Details)


Date

19 Aug 2024

Mark Type

US

Legal History


Show more

Status DateAction Taken
18th Mar 2025Application Accepted correspondence sent
17th Mar 2025IP Right has been Examined
17th Mar 2025IP Right Acceptance Published
17th Mar 2025Status change to Accepted
6th Mar 2025Awaiting examination
6th Mar 2025Examination expedited
6th Mar 2025IP Right Filed Published
6th Mar 2025Status change to Published
6th Mar 2025Status change to Filed
6th Mar 2025Application Received